Treatment Continuity Act of 2025

The Treatment Continuity Act of 2025 would authorize the Secretary of Health and Human Services to address priority treatment needs for substance use disorders (SUD) and serious mental illness (SMI) through grants that focus on long-acting injectable medications. The bill expands the existing priority-treatment program to explicitly include SMI alongside SUD and requires that grants support access to FDA-approved long-acting injectables, accompanying lab testing and supportive counseling, and training on the use of these medications in conjunction with related clinical services. It also establishes an annual reporting requirement to Congress on program outcomes and progress, and it applies the amendments to grants made under the program after the bill’s enactment. In short, the bill aims to advance treatment continuity by promoting longer-acting pharmacotherapies plus essential lab work, counseling, and provider training, with heightened federal oversight through regular reports to Congress. It places emphasis on improving regional and national treatment outcomes for both SUD and SMI.